Journal
BLOOD
Volume 113, Issue 24, Pages 6061-6068Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-12-197061
Keywords
-
Categories
Funding
- Hope Street Kids
- Leukemia & Lymphoma Society
- American Society of Clinical Oncology Foundation Contribution
Ask authors/readers for more resources
Treatment of hematologic malignancies is evolving from a uniform approach to targeted therapies directed at the underlying molecular abnormalities of disease. The mixed lineage leukemia (MLL) protooncogene is a recurrent site of genetic rearrangements in acute leukemias; and since its discovery in 1992, many advances have been made in understanding its role in leukemogenesis. A variety of MLL translocation partners have been described, and detailed structure/function studies have identified functional domains that are required for transformation. Proteins associated with the MLL core complex or its fusion partners have been isolated and characterized for their critical roles in leukemia pathogenesis. Downstream mediators of MLL transcriptional regulation and multiple collaborating signaling pathways have been described and characterized. These advances in our understanding of MLL-related leukemogenesis provide a foundation for ongoing and future efforts to develop novel therapeutic strategies that will hopefully result in better treatment outcomes. (Blood. 2009; 113: 6061-6068)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available